Peter J Brown Is Appointed President of Reverba

Reverba, a leading global patient engagement company, today announced the appointment of Peter J. Brown, MBA, as President. He brings more than 20 years of experience in life sciences, healthcare and patient engagement, with a track record of driving growth in highly complex, competitive markets and successfully scaling organizations to support expanding service and product offerings.

“We are delighted to welcome Peter to Reverba. His experience enhances the leadership team and strengthens our ability to transform the way biopharmaceutical companies think and function by incorporating compliant, patient-centered action at the core of their business,” said Cheryl Lubbert, CEO and co-founder of Reverba. “Peter brings the ideal skills we need to accelerate our growth and deliver value for healthcare organizations and patients.”

Peter J Brown joins Reverba at an exciting time, as the company is expanding its proprietary, compliant patient engagement solutions and services to connect biopharma companies with patients to amplify the impact of patient voices.

“I am excited to take on this role at Reverba, a foundational company that helped create the patient engagement space,” said Peter J Brown, President of Reverba. “I see an extraordinary opportunity for Reverba to expand the company’s offerings, built on deep understanding of secure technology solutions that enable meaningful connections with patients.”

Brown joins Reverba from his role as President, Chief Executive Officer and General Manager of Thornberry, provider of hospice and home health software solutions, where he drove market strategy, product development, operations and sales against aggressive financial and operational performance targets, leading two major platform technology initiatives and significant product enhancements. Concurrently, he was Founder and President of Proinligo Consulting, providing support to payers, providers and health systems for digital health services and engagement. He is a Fellow of the Academy for Healthcare Management and holds a Bachelor of Economics from Union College and an MBA in Management from McDonough School of Business, Georgetown University.

SourceReverba

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”